Lantern Pharma Inc.
LTRNNASDAQHealthcare● Active
$3.75
+$0.16(+4.46%)
Market Cap$47845770
P/E Ratio—
52W High$5.744
52W Low$1.11
Lantern Pharma Inc. (LTRN) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
LTRN · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$0.30
Est. -$0.36 · +16.7%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
▲ Beat EPS🔥 5-Quarter EPS Beat Streak
LTRN reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 12, 2026 | -$0.38 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 15, 2026 | -$0.36 | -$0.30 | +16.7% | — | — | — |
| ▲ Q1 FY2026 | Mar 30, 2026 | -$0.46 | -$0.36 | +21.7% | — | — | — |
| ▲ Q4 FY2025 | Nov 12, 2025 | -$0.46 | -$0.39 | +15.2% | — | — | — |
| ▲ Q3 FY2025 | Aug 13, 2025 | -$0.53 | -$0.40 | +24.5% | — | — | — |
| ▲ Q2 FY2025 | May 15, 2025 | -$0.49 | -$0.42 | +14.3% | — | — | — |
| ▼ Q1 FY2025 | Mar 27, 2025 | -$0.51 | -$0.54 | -5.9% | $0.00B | — | — |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$0.56 | -$0.42 | +25.0% | — | — | — |
Q3 FY2026
Aug 12, 2026
EPS Actual
—
EPS Est.
-$0.38
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026Beat
EPS Actual
-$0.30
EPS Est.
-$0.36
EPS Surpr.
+16.7%
Revenue
—
Q1 FY2026
Mar 30, 2026Beat
EPS Actual
-$0.36
EPS Est.
-$0.46
EPS Surpr.
+21.7%
Revenue
—
Q4 FY2025
Nov 12, 2025Beat
EPS Actual
-$0.39
EPS Est.
-$0.46
EPS Surpr.
+15.2%
Revenue
—
Q3 FY2025
Aug 13, 2025Beat
EPS Actual
-$0.40
EPS Est.
-$0.53
EPS Surpr.
+24.5%
Revenue
—
Q2 FY2025
May 15, 2025Beat
EPS Actual
-$0.42
EPS Est.
-$0.49
EPS Surpr.
+14.3%
Revenue
—
Q1 FY2025
Mar 27, 2025Miss
EPS Actual
-$0.54
EPS Est.
-$0.51
EPS Surpr.
-5.9%
Revenue
$0.00B
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
-$0.42
EPS Est.
-$0.56
EPS Surpr.
+25.0%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.44 | $-0.44 | $-0.44 | 1 |
| Q3 FY2026 | $-0.38 | $-0.38 | $-0.38 | 1 |
| Q2 FY2026 | $-0.38 | $-0.38 | $-0.38 | 1 |
| Q1 FY2026 | $-0.36 | $-0.36 | $-0.36 | 1 |
| Q4 FY2025 | $-0.46 | $-0.46 | $-0.46 | 1 |
| Q3 FY2025 | $-0.47 | $-0.47 | $-0.47 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 15, 2026 | +16.7% | $3.13 | $3.14 | +0.32% |
| ▲ Q1 FY2026 | Mar 30, 2026 | +21.7% | $1.12 | $1.24 | +10.71% |
| ▲ Q4 FY2025 | Nov 12, 2025 | +15.2% | $3.54 | $3.48 | -1.69% |
| ▲ Q3 FY2025 | Aug 13, 2025 | +24.5% | $4.45 | $4.76 | +6.97% |
| ▲ Q2 FY2025 | May 15, 2025 | +14.3% | $4.06 | $3.86 | -4.93% |
| ▼ Q1 FY2025 | Mar 27, 2025 | -5.9% | $3.65 | $3.72 | +1.92% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +25.0% | $3.31 | $3.42 | +3.32% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +16.4% | $4.03 | $4.23 | +4.96% |
Q2 FY2026+0.32%
Report Date
May 15, 2026
EPS Beat/Miss
+16.7%
Price Before
$3.13
Price After
$3.14
Q1 FY2026+10.71%
Report Date
Mar 30, 2026
EPS Beat/Miss
+21.7%
Price Before
$1.12
Price After
$1.24
Q4 FY2025-1.69%
Report Date
Nov 12, 2025
EPS Beat/Miss
+15.2%
Price Before
$3.54
Price After
$3.48
Q3 FY2025+6.97%
Report Date
Aug 13, 2025
EPS Beat/Miss
+24.5%
Price Before
$4.45
Price After
$4.76
Q2 FY2025-4.93%
Report Date
May 15, 2025
EPS Beat/Miss
+14.3%
Price Before
$4.06
Price After
$3.86
Q1 FY2025+1.92%
Report Date
Mar 27, 2025
EPS Beat/Miss
-5.9%
Price Before
$3.65
Price After
$3.72
Q4 FY2024+3.32%
Report Date
Nov 7, 2024
EPS Beat/Miss
+25.0%
Price Before
$3.31
Price After
$3.42
Q3 FY2024+4.96%
Report Date
Aug 8, 2024
EPS Beat/Miss
+16.4%
Price Before
$4.03
Price After
$4.23
Avg Beat Reaction+2.81%
Avg Miss Reaction+1.92%
Beat Rate7 / 8 quarters
Largest Move+10.71% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: LTRN ends December
Lantern Pharma Inc. (LTRN) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-0.30 — beating the analyst consensus of $-0.36 by +16.7%. LTRN has beaten EPS estimates for 5 consecutive quarters. The next LTRN earnings date is expected around September 1, 2026.
Each quarter, investors track LTRN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. LTRN revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
LTRN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
LTRN earnings · 5 questionsLantern Pharma Inc.'s next earnings report is expected around September 1, 2026. LTRN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; LTRN historically reports after market close (AMC).
LTRN earnings datewhen is LTRN earningsLTRN next earnings datewhen does LTRN report earningsLTRN earnings calendar
▸ Source: FMP · Lantern Pharma Inc. SEC filings · US GAAP · Lantern Pharma Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026